Menu Search
Equities

Amicus Therapeutics Inc

AM6:BER

Amicus Therapeutics Inc

Actions
  • Price (EUR)9.30
  • Today's Change-0.10 / -1.06%
  • Shares traded500.00
  • 1 Year change-23.77%
  • Beta--
Data delayed at least 15 minutes, as of Jul 23 2024 07:04 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amicus Therapeutics Inc grew revenues 21.30% from 329.23m to 399.36m while net income improved from a loss of 236.57m to a smaller loss of 151.58m.
Gross margin89.62%
Net profit margin-34.73%
Operating margin-19.18%
Return on assets-20.68%
Return on equity-126.10%
Return on investment-25.76%
More ▼

Cash flow in USDView more

In 2023, Amicus Therapeutics Inc increased its cash reserves by 63.33%, or 96.96m. Cash Flow from Investing totalled 98.06m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 69.09m for operations while cash generated from financing totalled 61.68m.
Cash flow per share-0.464
Price/Cash flow per share--
Book value per share0.4413
Tangible book value per share-0.293
More ▼

Balance sheet in USDView more

Amicus Therapeutics Inc has a Debt to Total Capital ratio of 74.82%, a lower figure than the previous year's 382.81%.
Current ratio3.03
Quick ratio2.61
Total debt/total equity2.97
Total debt/total capital0.7482
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.